Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0008031 (
chest pain
)
17,248
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To determine the clinical utility of human
ventricular myosin light chain 1
(HVLC1) in the diagnosis of myocardial necrosis, we established a radioimmunoassay for serum HVLC1 using polyclonal antibodies raised against the purified human protein. HVLC1 levels were measured in sera from 110 control patients and 38 patients immediately after cardiovascular surgery and in serial specimens from 10 patients with uncomplicated myocardial infarctions. The HVLC1 assay was found to be equal in sensitivity for the first 48 hours to the CK-MB for myocardial necrosis after cardiovascular surgery and for myocardial infarction. In virtually all myocardial infarct patients, HVLC1 levels in sera rose within hours of the onset of
chest pain
. From thereon, two sub-trends were discerned. For many, the HVLC1 levels remain elevated for 9-12 days beyond. In some, the HVLC1 levels returned to normal levels 1-2 days after the initial rise, but became elevated again for the next 5-9 days. In either instance, the diagnosis of myocardial infarction was permitted as late as 10-12 days after the onset of
chest pain
which is in stark contrast to all conventionally used biochemical markers.
...
PMID:The quantitation of human ventricular myosin light chain 1 in serum after myocardial necrosis and infarction. 275 84
To determine if the presence of cardiac light chains in blood could be used to detect acute myocardial infarction, we developed a specific light chain immunoassay. A synthetic peptide sequence specific for human cardiac
ventricular myosin light chain 1
(
VLC1
) was synthesized and designated P348. This peptide coupled to keyhole limpet hemocyanin was used as an immunogen to obtain murine monoclonal antibodies specific for
VLC1
. Five monoclonal antibodies were obtained. One of these designated Mab-8E3 reacted equally well with both the synthetic peptide and
VLC1
. Although the 8E3 antibody is specific for
VLC1
, the use of HPLC purification of skeletal muscle myosin light chain 1 demonstrated that
VLC1
is present in human skeletal muscle. The clinical utility of the assay was tested in 18 patients with creatine kinase (CK) and ECG documented acute myocardial infarction.
VLC1
was below the limit of detection (< 1 ng/ml) in sera obtained from healthy volunteers and patients without myocardial infarction or
chest pain
. In contrast
VLC1
was elevated in the serum of all 18 patients with acute myocardial infarction. Combining the two test results at the time of admission resulted in 83% of patients having detectable serum levels of one or both markers.
...
PMID:Synthetic peptide immunogens for the development of a cardiac myosin light chain-1 specific radioimmunoassay. 825 2